ChemicalBook Product Catalog API Synthetic Anti-infective Drugs Antiviral drugs Oseltamivir

1/1

Oseltamivir NEW

$2.00 100kg

$4.00 10kg

$6.00 1kg

Min. Order1kg
Purity99%
Cas No196618-13-0
Supply Ability100kg
Update time2025-10-13

ZHENGZHOU JIUYI TIME NEW MATERIALS CO,.LTD

VIP1Y

China

Chemical Properties

Product Name	Oseltamivir
CAS No	196618-13-0
EC-No
Min. Order	1kg
Purity	99%
Supply Ability	100kg
Release date	2025/10/13

PRODUCT INFORMATION

Common Name	Oseltamivir
CAS Number	196618-13-0	Molecular Weight	312.40
Density	1.2±0.1 g/cm3	Boiling Point	445.4±55.0 °C at 760 mmHg
Molecular Formula	C16H28N2O4	Melting Point	109 °C
MSDS	N/A	Flash Point	223.2±31.5 °C

Purity		Quantity		Budget		Inquiry

Use of Oseltamivir

Oseltamivir (GS 4104) is an orally active influenza virus neuraminidase inhibitor (NAI). Oseltamivir inhibits influenza A/H3N2, A/H1N2, A/H1N1, and B viruses with mean IC50s of 0.67, 0.9, 1.34 and 13 nM, respectively[1].

Properties
Spectrum

Name	oseltamivir
Synonym	More Synonyms

Description	Oseltamivir (GS 4104) is an orally active influenza virus neuraminidase inhibitor (NAI). Oseltamivir inhibits influenza A/H3N2, A/H1N2, A/H1N1, and B viruses with mean IC50s of 0.67, 0.9, 1.34 and 13 nM, respectively[1].
Related Catalog	Signaling Pathways >> Anti-infection >> Influenza Virus Research Areas >> Infection
References	[1]. O Ferraris, et al. Sensitivity of Influenza Viruses to Zanamivir and Oseltamivir: A Study Performed on Viruses Circulating in France Prior to the Introduction of Neuraminidase Inhibitors in Clinical Practice. Antiviral Res. 2005 Oct;68(1):43-8. [2]. Smee DF, et al. Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice. Antiviral Res. 2016 Dec;136:45-50. [3]. Ilyushina NA, et al. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther. 2007;12(3):363-70. [4]. Ilyushina NA, et al. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother. 2008 Nov;52(11):3889-97. [5]. Smee DF, et al. Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. Antiviral Res. 2010 Oct;88(1):38-44.

Description

Related Catalog

Signaling Pathways >> Anti-infection >> Influenza Virus

Research Areas >> Infection

References

[1]. O Ferraris, et al. Sensitivity of Influenza Viruses to Zanamivir and Oseltamivir: A Study Performed on Viruses Circulating in France Prior to the Introduction of Neuraminidase Inhibitors in Clinical Practice. Antiviral Res. 2005 Oct;68(1):43-8.

[2]. Smee DF, et al. Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice. Antiviral Res. 2016 Dec;136:45-50.

[3]. Ilyushina NA, et al. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther. 2007;12(3):363-70.

[4]. Ilyushina NA, et al. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother. 2008 Nov;52(11):3889-97.

[5]. Smee DF, et al. Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. Antiviral Res. 2010 Oct;88(1):38-44.

Density	1.2±0.1 g/cm3
Boiling Point	445.4±55.0 °C at 760 mmHg
Melting Point	109 °C
Molecular Formula	C16H28N2O4
Molecular Weight	312.40
Flash Point	223.2±31.5 °C
Exact Mass	312.204895
PSA	90.65000
LogP	2.52
Vapour Pressure	0.0±2.4 mmHg at 25°C
Index of Refraction	1.529

ethyl (3R,4R,5S...

312904-18-0

~71%

Oseltamivir

196618-13-0

Literature: Karpf, Martin; Trussardi, Rene Patent: US2006/47002 A1, 2006 ; Location in patent: Page/Page column 7 ;

(3R,4R,5S)-ethy...

1197396-47-6

~98%

Oseltamivir

196618-13-0

Literature: Tokyo University Of Science Educational Foundation Administrative Organization Patent: EP2301911 A1, 2011 ; Location in patent: Page/Page column 32-33 ;

5-Azido Oseltam...

204255-06-1

~97%

Oseltamivir

196618-13-0

Literature: Roche Palo Alto LLC Patent: US2009/76296 A1, 2009 ; Location in patent: Page/Page column 9 ;

Precursor 6	Previous 1/2 Next
CAS#:312904-18-0 ethyl (3R,4R,5S... CAS#:204255-06-1 5-Azido Oseltamivir CAS#:1041262-68-3 ethyl (3R,4R,5S... CAS#:367252-68-4 oseltamivir
DownStream 1
CAS#:204255-11-8 Oseltamivir pho...

OSELTAMIVIR

(3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester

Oseltamivir (free base)

TaMvir

GOP-A-Flu

(3R,5S)-ethyl 4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylate

TaMiflu-Free

TAMIFLU

(3R,4R,5S)-4-acetylamino-5-amino-3(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester

OSTELTAMIVIR

(3R,4R,5S)-5-amino-4-acetylamino-3-(1-ethyl-propoxy)-cyclohex-1-ene-carboxylic acid ethyl ester

GS 4104

ethyl (3R,4R,5S)-5-aMino-4-acetaMido-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate

[14C]-Oseltamivir

ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate

Company Profile

Our company is a high-tech enterprise specializing in chemical raw materials such as electronic materials, optoelectronic materials, semiconductor materials, UV monomers, silane catalysts, cosmetic raw materials, etc. The company integrates research and development, production, customized synthesis, and sales, and is committed to providing customers with high-quality chemical product solutions.

Our Company

Our Advantage

Rich experience

Our products have been exported to many countries, including Germany, Spain, the United Kingdom, the United States, Australia, the Middle East, Asia, and more. We have received highly positive feedback from our clients and have established long-term friendly cooperative relationships with them.

Excellent quality, purity, and competitive price

Excellent quality is one of the cornerstones of our success. We welcome ordering samples for quality testing.